iSmartNetwork Magazine The online magazine for you…
NEW DELHI: Nourished by increasing spending, improving accessibility and growing exportations, India’s pharma and healthcare sector is poised for another year of robust proliferation even as pricing and cost headwinds could force players to pause to catch breath. The next ripple of growing could come from increasing exports to large and traditionally under penetrated sells such as Japan, China, Africa, Indonesia, and Latin american countries, which would help the industry meet its aspiration of becoming the world’s largest supplier by volume, according to pharma industry figure Indian Pharmaceutical Alliance( IPA ). Experts said improved access to medicines in India and exploring brand-new marketplaces while maintaining thrust in the US will help the country’s pharma industry to record double-digit growth in the coming years. However, key sectors, specially medicines, will be up against headwinds of increased costs related to regulatory conformities, especially for the US market, price control across markets and mandatory genericisation in India. “The Indian Pharmaceutical industry is a sunrise industry with a competitive edge for India. We should leverage India’s position by unleashing entrepreneurial spirit through policy stability and ecosystem, ” IPA Secretary General Sudarshan Jain said. The bullish outlook for the sector is also reflected in the forecast by rating agency Icra, which has projected the Indian pharmaceutical industry to grow around 10 -1 2 per cent between FY2019 and FY2022 while maintaining a stable outlook on the sector. It quoth slaking headwinds from pricing pressure in the US( which is the largest regulated market ), stable proliferation for the Indian market driven by increasing healthcare spending and better accessibility as likely key growing drivers for the Indian pharma companies, coupled with comfy balance sheet structure. As for the healthcare sector, Apollo Infirmary Group MD Suneeta Reddy said, “The prognosis is positive.” The optimism is driven by the Indian government’s thrust on universal healthcare through Ayushman Bharat and an increasing number of middle-class trying excellence and affordable healthcare, along with the ability of private payers to attract world patients. Reddy said the private Indian healthcare providers are also ready to play their part in accelerating the country’s economic growth. ” … the sector is capable of delivering strong impetus for India’s economy at a time when the country needs to hear good report on the economic front, ” she noted. Reddy cited the capacity of private healthcare providers to create five direct occupations plus many more indirect chores per bed, two and half hours multiplier on capital invested along with global prestige and stature driven by the Medical Value Travel programmes as key strengths of key sectors. Having gone through 2019, during which domestic medication firms came under the scanner of the US health regulator — US Food and Drug Administration( USFDA) — which red-flagged homegrown majors like Aurobindo Pharma, Torrent Medication, Glenmark Pharmaceuticals, and Cadila Healthcare, amongst other for mistakes at their facilities, the challenges remain real. Yes Protection Senior Analyst – Institutional Equities – Bhavesh Gandhi said, “pharma sector continued to show divergent trends in 2019 with the domestic market growing at a steady 9-10 per cent run rate offset by persistent challenges in US generics”. Most of the domestic-focused corporations heard health traction in revenues on the back of market tailwinds, he said. The US business has proved to be a tough task for yet another year as structural headwinds still persisted despite the flattening out of price erosion at 5-6 per cent of members as compared to steeper falls in earlier years, he added. Max Healthcare& Radiant Life Care Chairman& MD Abhay Soi said in 2020, the world and domestic demand for quality and cost-effective healthcare services is expected to grow further. The Indian healthcare sector has the potential to be amongst the highest revenue and employment generator for the country. “A shift towards patient-centric quality care, enhanced use of technology in deliver care, and higher share of India in medical tourism are some of the dominant trends which the Indian healthcare sector is going to witness in 2020, ” he noted. As for the service providers, he said, “I believe, in 2020 and onwards, the main differentiator would be patient care and service. Healthcare institutions would be focusing on all the key touchpoints of the entire patient journey”. Highlighting the priorities, Healthcare Federation of India( NATHEALTH) President Sudarshan Ballal said that in 2020, ‘Health for Healthcare’ would be the main mantra for all stakeholders including policymakers and regulators. “Balancing sustainability, promoting the quality, and appreciate initiation would be the top priorities for the sector. It is necessary for quality healthcare to be delivered to everybody in India, hence incentivising capacity building in Tier II& III metropolitans would go a long way in achieving the goal of universal healthcare, ” he added. Healthcare in India is on the cusp of significant metamorphosi — demographic, regulatory, technological and financial — Organisation of Pharmaceutical Producers of India( OPPI) President A Vaidheesh said. Indian government’s thrust on universal healthcare through Ayushman Bharat and an estimated 140 million households expected to enter the middle class in the next decade , is not simply increases the intake of healthcare services but also has an impact on healthcare demand and a significant uptake inpatient volumes, he added. While it seems all hunky-dory, medical devices producers crave issues affecting them to be addressed satisfactorily. Medical machines makers’ body, AdvaMed Vice President Abby Pratt said it would advise the government to promote the adoption of world harmonisation, including internationally recognised standards, that would not only help ensure the quality and efficacy of products but also enable an ecosystem for manufacturing, experiment, and invention for benefits of patients in India.
Read more: economictimes.indiatimes.com
